Poseida Therapeutics (NASDAQ:PSTX) Receives Neutral Rating from HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Poseida Therapeutics (NASDAQ:PSTX) in a research note published on Tuesday,Benzinga reports. The firm currently has a $9.00 price objective on the stock, down from their prior price objective of $20.00.

Poseida Therapeutics Stock Performance

Shares of Poseida Therapeutics stock opened at $9.38 on Tuesday. The company’s 50 day moving average price is $2.90 and its two-hundred day moving average price is $2.97. The firm has a market capitalization of $914.17 million, a P/E ratio of -14.89 and a beta of 0.54. Poseida Therapeutics has a fifty-two week low of $1.87 and a fifty-two week high of $9.41. The company has a debt-to-equity ratio of 0.68, a current ratio of 3.20 and a quick ratio of 3.20.

Hedge Funds Weigh In On Poseida Therapeutics

Large investors have recently bought and sold shares of the company. Marshall Wace LLP bought a new stake in shares of Poseida Therapeutics during the second quarter worth about $31,000. Bayesian Capital Management LP bought a new stake in Poseida Therapeutics during the 1st quarter worth approximately $33,000. Rothschild Investment LLC bought a new stake in Poseida Therapeutics during the 2nd quarter worth approximately $35,000. Principal Financial Group Inc. acquired a new position in Poseida Therapeutics in the 2nd quarter valued at approximately $35,000. Finally, Virtu Financial LLC acquired a new position in shares of Poseida Therapeutics during the third quarter worth $37,000. 46.87% of the stock is currently owned by institutional investors.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.